IRIS
BARILLARI, GIOVANNI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 28.270
AS - Asia 2.901
EU - Europa 2.601
SA - Sud America 401
AF - Africa 39
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 4
Totale 34.222
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 28.207
SG - Singapore 1.511
CN - Cina 600
DE - Germania 474
IT - Italia 397
UA - Ucraina 397
RU - Federazione Russa 361
BR - Brasile 336
IE - Irlanda 287
HK - Hong Kong 235
VN - Vietnam 215
FR - Francia 181
GB - Regno Unito 134
PL - Polonia 110
JP - Giappone 92
FI - Finlandia 75
SE - Svezia 49
IN - India 44
NL - Olanda 41
KR - Corea 36
CA - Canada 33
BD - Bangladesh 29
ID - Indonesia 29
AR - Argentina 25
MX - Messico 21
ES - Italia 19
TW - Taiwan 19
AT - Austria 18
TR - Turchia 17
IQ - Iraq 16
ZA - Sudafrica 16
BE - Belgio 12
PH - Filippine 10
EC - Ecuador 9
PK - Pakistan 8
AL - Albania 7
CL - Cile 7
CO - Colombia 7
CZ - Repubblica Ceca 7
AU - Australia 6
TH - Thailandia 6
DK - Danimarca 5
EG - Egitto 5
MA - Marocco 5
UZ - Uzbekistan 5
VE - Venezuela 5
LT - Lituania 4
PE - Perù 4
BO - Bolivia 3
CH - Svizzera 3
CI - Costa d'Avorio 3
DZ - Algeria 3
EU - Europa 3
JO - Giordania 3
KE - Kenya 3
LB - Libano 3
MY - Malesia 3
PY - Paraguay 3
RO - Romania 3
SA - Arabia Saudita 3
TT - Trinidad e Tobago 3
AE - Emirati Arabi Uniti 2
BG - Bulgaria 2
BS - Bahamas 2
BY - Bielorussia 2
GR - Grecia 2
HU - Ungheria 2
JM - Giamaica 2
KZ - Kazakistan 2
LV - Lettonia 2
NP - Nepal 2
RS - Serbia 2
TN - Tunisia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
AZ - Azerbaigian 1
DO - Repubblica Dominicana 1
FK - Isole Falkland (Malvinas) 1
GE - Georgia 1
GY - Guiana 1
HN - Honduras 1
HR - Croazia 1
IL - Israele 1
IR - Iran 1
KG - Kirghizistan 1
KW - Kuwait 1
LK - Sri Lanka 1
LU - Lussemburgo 1
LY - Libia 1
MD - Moldavia 1
MK - Macedonia 1
MN - Mongolia 1
MZ - Mozambico 1
OM - Oman 1
QA - Qatar 1
SI - Slovenia 1
Totale 34.222
Salva come PNG Salva come JPEG
Città #
Wilmington 7.703
Woodbridge 7.442
Houston 6.808
Singapore 904
Fairfield 619
Chandler 577
Ashburn 427
Ann Arbor 391
San Jose 378
Dearborn 318
Dublin 267
Hong Kong 228
Seattle 227
Cambridge 210
Jacksonville 207
Medford 199
Beijing 194
New York 188
Rome 154
Santa Clara 146
Los Angeles 142
Chicago 110
Council Bluffs 101
Lawrence 93
Kraków 88
Buffalo 87
The Dalles 83
Tokyo 74
Menlo Park 70
Zhengzhou 70
Dallas 66
Ho Chi Minh City 66
Lauterbourg 66
Hanoi 57
San Diego 53
Moscow 52
Salt Lake City 46
Helsinki 35
São Paulo 33
Boardman 29
Milan 29
Nuremberg 27
Frankfurt am Main 26
Redondo Beach 24
Jakarta 22
Phoenix 21
Tampa 21
Elk Grove Village 19
Mülheim 19
Warsaw 19
Chennai 18
Guangzhou 18
Orem 18
Redwood City 17
Nanjing 16
Atlanta 15
Norwalk 15
Lappeenranta 14
Shanghai 14
London 13
Montreal 13
Verona 13
Boston 12
Brussels 12
Dulles 12
Mountain View 12
Manchester 11
Munich 11
San Francisco 11
Sterling 11
Stockholm 11
Amsterdam 9
Center 9
Columbus 9
Johannesburg 9
Baghdad 8
Brasília 8
Brooklyn 8
Da Nang 8
Detroit 8
Haiphong 8
Kaohsiung 8
Poplar 8
Rio de Janeiro 8
Toronto 8
Wuhan 8
Belo Horizonte 7
Colorado Springs 7
Denver 7
Mexico City 7
Miami 7
Mumbai 7
Philadelphia 7
Seoul 7
University Park 7
Vienna 7
Washington 7
Biên Hòa 6
Frankfurt Am Main 6
Hefei 6
Totale 29.741
Salva come PNG Salva come JPEG
Nome #
Detection of high nerve growth factor serum levels in AIDS-related and -unrelated Kaposi's sarcoma patients 523
Correlation between pathological data and the RNA expression of p53 or p53-targeted genes in primary invasive ductal breast carcinomas: a preliminary study 493
HTLV-V: a new human retrovirus isolated in a Tac-negative T cell lymphoma/leukemia 482
Ritonavir or saquinavir impairs the invasion of cervical intraepithelial neoplasia cells via a reduction of MMP expression and activity. 468
Native HIV-1 Tat protein targets monocyte-derived dendritic cells and enhances their maturation, function, and antigen-specific T cell responses 460
Fibroblast growth factor-2 transiently activates the p53 oncosuppressor protein in human primary vascular smooth muscle cells: implications for atherogenesis 457
The basic residues of placenta growth factor type 2 retrieve sequestered angiogenic factors into a soluble form: implications for tumor angiogenesis 449
HIV-1 Tat regulates endothelial cell cycle progression via activation of the Ras/ERK MAPK signaling pathway 446
Human T-lymphotropic retrovirus infection in Italy 439
The HIV protease inhibitor indinavir down-regulates the expression of the pro-angiogenic MT1-MMP by human endothelial cells 437
A tricistronic retroviral vector expressing natural antiangiogenic factors inhibits angiogenesis in vitro, but is not able to block tumor progression in vivo 435
Antitumor effects of antiretroviral therapy 431
Immobilized HIV-1 Tat protein promotes gene transfer via a transactivation independent mechanism which requires binding of Tat to viral particles 430
Fibroblast growth factor-2 and the HIV-1 Tat protein synergize in promoting Bcl-2 expression and preventing endothelial cell apoptosis: implications for the pathogenesis of AIDS-associated Kaposi’s sarcoma. 430
The fibroblast growth factors. 430
Pharmacological management of Kaposi’s sarcoma. 428
Inflammatory cytokines stimulate vascular smooth muscle cells locomotion and growth by enhancing alpha5beta1 integrin expression and function 427
Inhibition of MMP-9 expression by ritonavir or saquinavir is associated with inactivation of the AKT/Fra-1 pathway in cervical intraepithelial neoplasia cells 419
Pathogenesis of AIDS-associated Kaposi's sarcoma 418
Fibroblast growth factor-2 transiently activates the p53 oncosuppressor protein in human primary vascular smooth muscle cells: implications for atherogenesis. 417
Spindle cells from Acquired Immune Deficiency Syndrome-associated Kaposi’s sarcoma lesions express telomerase activity directly relating to the RNA levels of fibroblast growth factor-2. 415
Block of AIDS-Kaposi's sarcoma (KS) cell growth, angiogenesis, and lesion formation in nude mice by antisense oligonucleotide targeting basic fibroblast growth factor. A novel strategy for the therapy of KS 409
Another mechanism involved in AIDS-KS progression. 408
HIV-1 Tat addresses dendritic cells to induce a predominant Th1-type adaptive immune response that appears prevalent in the asymptomatic stage of infection 405
Entrance of the tat protein of HIV-1 into human uterine cervical carcinoma cells causes upregulation of HPV-E6 expression and a decrease in p53 protein levels 399
Molecular mechanisms in the pathogenesis of AIDS-associated Kaposi's sarcoma 397
Angiogenic properties of human immunodeficiency virus type 1 Tat protein 392
Follow-up study of patients with cervical intraepithelial neoplasia grade 1 overexpressing p16ink4a. 387
Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth 386
Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients 385
HTLV-I and HIV infection in drug addicts in Italy 385
Treatment of Kaposi's sarcoma--an update 385
HIV protease inhibitors as new treatment options for Kaposi's sarcoma 383
Human immunodeficiency virus protease inhibitors reduce the growth of human tumors via proteasome-independent block of angiogenesis and matrix metalloproteinases. 379
Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation 373
Angiogenic effects of extracellular human immunodeficiency virus type 1 Tat protein and its role in the pathogenesis of AIDS-associated Kaposi's sarcoma 372
Transcription of placenta growth factor type-2 correlates with intratumoral microvessel density in breast carcinomas. 371
The helical domain of GBP-1 mediates the inhibition of endothelial cell proliferation by inflammatory cytokines 369
Clinical course of classic Kaposi's sarcoma in HIV-negative patients treated with the HIV protease inhibitor indinavir 367
Activation of matrix-metalloproteinase-2 and membrane-type-1-matrix-metalloproteinase in endothelial cells and induction of vascular permeability in vivo by human immunodeficiency virus-1 Tat protein and basic fibroblast growth factor 364
The Tat protein of human immunodeficiency virus type 1, a growth factor for AIDS Kaposi sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence 363
HTLV-I is endemic in southern Italy: detection of the first infectious cluster in a white population 361
Spindle cells from AIDS-associated Kaposi's sarcoma (KS) lesions express telomerase activity that is enhanced by KS progression factors. 359
Basic fibroblast growth factor modifies the interactions between endothelial cells/fibronectin: Implications for progression of AIDS- associated Kaposi's sarcoma 358
Human T-lymphotropic retroviruses: a new member of the family. 357
Basic fibroblast growth factor mediates the growth and angiogenic activity of AIDS-Kaposi’s sarcoma (KS)-derived spindle cells and synergises with HIV-1 Tat protein in inducing KS-like lesions in mice. 353
HIV protease inhibitors block angiogenesis and promote regression of Kaposi’s sarcoma in the nude mouse model. 351
Tat, the transactivator gene of HIV-1, activates the expression of tumor necrosis factor-beta. 350
The use of HAART for biological tumour therapy 348
null 345
Release and angiogenic properties of extracellular HIV-1 Tat protein. 345
Cytokines and growth factors in the pathogenesis of AIDS-associated Kaposi's sarcoma 343
Release-uptake of HIV-1 Tat and mechanisms of Tat-induced paracrine biological effects (TAT domains and pathways for cell growth and transactivation activity). 339
Immune activation, rather than immune deficiency, cooperates with HIV infection in the development of AIDS-associated Kaposi’s sarcoma. 338
Immobilized HIV-1 Tat protein promotes gene transfer via a transactivation independent mechanism which requires binding of Tat to viral particles. 333
Lymphokines released by activated or HTLV-infected T cells induce growth of normal mesenchymal cells and of cells derived from Kaposi’s sarcoma lesions of AIDS patients. 331
Biological properties of Human Immunodeficiency Virus type-1 Tat protein: angiogenic effects and adhesive interactions of extracellular Tat. 331
The formation of new blood vessels in Kaposi’s sarcoma. 325
Biology of Kaposi's sarcoma 325
IFN-gamma induces endothelial cells to proliferate and to invade the extracellular matrix in response to the HIV-1 Tat protein: implications for AIDS-Kaposi's sarcoma pathogenesis 325
Role of HIV-1 TAT gene product and of cytokines released by activated immune cells in the pathogenesis of AIDS-associated Kaposi’s sarcoma. 322
Multicistronic antiangiogenic retroviral vectors for the gene therapy of malignant brain tumors. 322
HIV protease inhibitors: antiretroviral agents with anti-inflammatory, anti-angiogenic and anti-tumour activity 321
PDGF-B as a possible growth factor in AIDS-KS. 321
Integrin-mediated uptake of HIV-1 Tat protein by cytokine-activated endothelial cells. 318
HIV-1 Tat protein mimics the effect of extracellular matrix (ECM) protein on vascular cell growth and angiogenesis: implications for AIDS-Kaposi’s sarcoma (AIDS-KS) pathogenesis. 318
Interactions between endothelial cells and HIV-1 317
Tissue CEA as prognostic indicator in a series of 31 cases of gastric cancer 317
Inflammatory cytokines synergize with the HIV-1 Tat protein to promote angiogenesis and Kaposi's sarcoma via induction of basic fibroblast growth factor and the alpha v beta 3 integrin 316
Mechanism of paclitaxel activity in Kaposi's sarcoma 314
HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma 314
[Chronic T-lymphocyte lymphatic leukemia. Clinico-pathologic assessment and new epidemiologic data related to cases correlated with HTLV-I in Italy] 314
The angiogenic properties of HIV-I Tat protein are mediated by two different domains. 311
Effects of the human immunodeficiency virus type 1 Tat protein on the expression of inflammatory cytokines 308
Effects of cytokines from activated immune cells on vascular cell growth and HIV-1 gene expression. Implications for AIDS-Kaposi's sarcoma pathogenesis 306
T-helper phenotype chronic lymphocytic leukaemia and "adult T-cell leukaemia" in Italy. Endemic HTLV-I-related T-cell leukaemias in southern Europe 304
Basic FGF induces lesions in mice resembling KS, and antisense oligonucleotides against this cytokine inhibit the growth and angiogenic activity of KS spindle cells. 304
[HIV protease inhibitors for the treatment of Kaposi's sarcoma] 297
The Tat protein of human immunodeficiency virus type-1 promotes vascular cell growth and locomotion by engaging the alpha5beta1 and alphavbeta3 integrins and by mobilizing sequestered basic fibroblast growth factor 296
Cytokines released by activated primary T cells stimulate the growth of AIDS-KS-derived cells and other cells of mesenchymal derivation. 296
Release-uptake of HIV-1 Tat and mechanisms of Tat-induced paracrine biological effects. 295
Role of cytokines from activated T cells and HIV-1 Tat protein in the pathogenesis of AIDS-associated Kaposi’s sarcoma. 294
HIV-1 Tat protein enhances angiogenesis and Kaposi’s sarcoma development triggered by inflammatory cytokines or bFGF by engaging the avb3 integrin. 291
Immune stimulation and HIV-1 infection have complementary effects in the induction and progression of AIDS-associated Kaposi’s sarcoma via release of cytokines and Tat. 288
Cooperation of HIV-1 Tat protein, inflammatory cytokines or bFGF in the pathogenesis of AIDS-Kaposis’s sarcoma. 273
Inflammatory cytokines increase mesenchymal cell growth and attachment induced by HIV-1 Tat protein and adhesion molecules: implications for AIDS-Kaposi’s sarcoma pathogenesis. 269
Activated peripheral blood lymphocytes produce factors promoting the growth of spindle cells derived from AIDS-associated Kaposi’s sarcoma. 252
About a Possible Impact of Endodontic Infections by Fusobacterium nucleatum or Porphyromonas gingivalis on Oral Carcinogenesis: A Literature Overview 203
Combined treatment with inhibitors of ErbB Receptors and Hh signaling pathways is more effective than single treatment in reducing the growth of malignant mesothelioma both in vitro and in vivo 177
Proteasome inhibition by bortezomib parallels a reduction in head and neck cancer cells growth, and an increase in tumor-infiltrating immune cells 175
Antitumoral effects of Bortezomib in malignant mesothelioma: evidence of mild endoplasmic reticulum stress in vitro and activation of T cell response in vivo 174
DNAM-1 chimeric receptor-engineered NK cells: a new frontier for CAR-NK cell-based immunotherapy 150
Infection by high-risk human papillomaviruses, epithelial-to-mesenchymal transition and squamous pre-malignant or malignant lesions of the uterine cervix: a series of chained events? 138
Correlation between pathological data and the RNA expression of p53 or p53-targeted genes in primary invasive ductal breast carcinomas: a preliminary study 127
Dietary Polyphenols Effects on Focal Adhesion Plaques and Metalloproteinases in Cancer Invasiveness 118
Combined mitoxantrone and anti-TGFβ treatment with PD-1 blockade enhances antitumor immunity by remodelling the tumor immune landscape in neuroblastoma 110
Radioresistance in rhabdomyosarcomas: much more than a question of dose 98
Biomarkers Identification in the Microenvironment of Oral Squamous Cell Carcinoma: A Systematic Review of Proteomic Studies 98
MYOD-SKP2 axis boosts tumorigenesis in fusion negative rhabdomyosarcoma by preventing differentiation through p57Kip2 targeting 97
Spermine oxidase induces DNA damage and sensitizes fusion negative rhabdomyosarcoma cells to irradiation 94
Totale 33.487
Salva come PNG Salva come JPEG
Categoria #
all - tutte 76.018
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 76.018
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021300 0 0 0 0 0 0 0 0 0 73 200 27
2021/2022919 19 130 13 63 18 43 48 119 32 54 85 295
2022/20231.326 159 110 100 143 97 276 113 80 123 43 68 14
2023/2024458 49 13 23 17 38 159 20 12 10 38 17 62
2024/20252.777 91 675 324 136 52 143 136 126 225 298 422 149
2025/20263.474 272 155 492 248 390 113 503 474 544 283 0 0
Totale 34.592